收稿日期: 2023-09-19
网络出版日期: 2024-02-22
基金资助
河北省自然科学基金项目(H2016201238);2019政府资助临床医学优秀人才培养项目(361007);河北大学医学学科重点项目(2020A11);河北大学附属医院2019年度院内基金项目(2019Z003)
Research progress of CD73/NT5E in glioblastoma
Received date: 2023-09-19
Online published: 2024-02-22
邵将 , 李琳 , 郭岩松 , 孙程圆 , 温稀超 , 郑克彬 , 史彦芳 . CD73/NT5E在胶质母细胞瘤中的研究进展[J]. 实用医学杂志, 2024 , 40(3) : 428 -431 . DOI: 10.3969/j.issn.1006-5725.2024.03.026
Glioma is the most common primary central nervous system tumor， mainly derived from glial cells， with strong invasiveness， easy recurrence， and poor prognosis. Glioblastoma is a high-grade glioma with the highest degree of malignancy. The clinical treatment method is mainly surgical resection， supplemented by comprehensive treatment such as radiotherapy， chemotherapy， and electric field therapy， but the treatment effect is not satisfactory. In recent years， with the rapid development of the field of tumor immunotherapy， CD73 is a novel immune checkpoint related to adenosine metabolism， which can promote tumor progression by inhibiting anti?tumor immune responses and promoting angiogenesis. This article systematically reviews the mechanism of action of CD73 and discusses its biological role and application in glioma， aiming to provide potential treatment options for glioma patients.
Key words： Glioblastoma; CD73/NT5E; adenosine; immune checkpoint; immunotherapy
| 1 | PARK J W. Metabolic Rewiring in Adult-Type Diffuse Gliomas［J］. Int J Mol Sci， 2023，24（8）： 7348. doi:10.3390/ijms24087348 |
| 2 | 曾昭穆，牛双，姬焱鑫，等. 长链非编码RNA多角度调控胶质瘤化疗耐药［J］. 实用医学杂志，2022，38（16）：1998-2001. doi:10.3969/j.issn.1006-5725.2022.16.003 |
| 3 | 李琳， 刘超， 邵将， 等. 肿瘤电场治疗在神经胶质瘤治疗中的研究进展［J］. 实用医学杂志， 2022，38（22）： 2763-2767. doi:10.3969/j.issn.1006-5725.2022.22.001 |
| 4 | VENKATESHAPPA C， NARAYANAN K， KOTHANDARAMAN P， et al. Novel， potent and orally bioavailable small molecule CD73 inhibitors for cancer immunotherapy［J］. Cancer Res， 2021，81（）： 1713. doi:10.1158/1538-7445.am2021-1713 |
| 5 | KEPP O， BEZU L， YAMAZAKI T， et al. ATP and cancer immunosurveillance［J］. EMBO J， 2021，40（13）： e108130. doi:10.15252/embj.2021108130 |
| 6 | SUWARA J， RADZIKOWSKA-CIECIURA E， CHWOROS A， et al. The ATP-dependent Pathways and Human Diseases［J］. Curr Med Chem， 2023，30（11）： 1232-1255. doi:10.2174/0929867329666220322104552 |
| 7 | XIA C， YIN S， TO K， et al. CD39/CD73/A2AR pathway and cancer immunotherapy［J］. Mol Cancer， 2023，22（1）： 44. doi:10.1186/s12943-023-01733-x |
| 8 | TAKAMATSU D， KIYOZAWA D， KOHASHI K， et al. Prognostic impact of CD73/adenosine 2A receptor （A2AR） in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features［J］. Pathol Res Pract， 2023，244： 154423. doi:10.1016/j.prp.2023.154423 |
| 9 | DA M， CHEN L， ENK A， et al. The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells［J］. Front Immunol， 2022，13： 914799. doi:10.3389/fimmu.2022.914799 |
| 10 | CHEN S， WAINWRIGHT D A， WU J D， et al. CD73： an emerging checkpoint for cancer immunotherapy［J］. Immunotherapy， 2019，11（11）： 983-997. doi:10.2217/imt-2018-0200 |
| 11 | SUN B Y， YANG Z F， WANG Z T， et al. Integrative analyses identify CD73 as a prognostic biomarker and immunotherapeutic target in intrahepatic cholangiocarcinoma［J］. World J Surg Oncol， 2023，21（1）： 90. doi:10.1186/s12957-023-02970-6 |
| 12 | BENSUSSEN A， SANTANA M A， RODRíGUEZ-JORGE O. Metabolic alterations impair differentiation and effector functions of CD8+ T cells［J］. Front Immunol， 2022，13： 945980. doi:10.3389/fimmu.2022.945980 |
| 13 | BYSTROM J， TAHER T E， HENSON S M， et al. Metabolic requirements of Th17 cells and of B cells： Regulation and defects in health and in inflammatory diseases［J］. Front Immunol， 2022，13： 990794. doi:10.3389/fimmu.2022.990794 |
| 14 | MAHESHWARI S， DWYER L J， S?RBULESCU R F. Inflammation and immunomodulation in central nervous system injury - B cells as a novel therapeutic opportunity［J］. Neurobiol Dis， 2023，180： 106077. doi:10.1016/j.nbd.2023.106077 |
| 15 | JANSEN K， CEVHERTAS L， MA S， et al. Regulatory B cells， A to Z［J］. Allergy， 2021，76（9）： 2699-2715. doi:10.1111/all.14763 |
| 16 | GAO Z， WANG L， SONG Z， et al. Intratumoral CD73： An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts［J］. Front Immunol， 2022，13： 954039. doi:10.3389/fimmu.2022.954039 |
| 17 | BRAUNECK F， SEUBERT E， WELLBROCK J， et al. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML［J］. Int J Mol Sci， 2021，22（23）：12919. doi:10.3390/ijms222312919 |
| 18 | SONIGO G， BOZONNAT A， DUMONT M， et al. Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sézary syndrome［J］. Blood， 2022，139（17）： 2712-2716. doi:10.1182/blood.2021014782 |
| 19 | KAMAI T， KIJIMA T， TSUZUKI T， et al. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival［J］. Cancer Immunol Immunother， 2021，70（7）： 2009-2021. doi:10.1007/s00262-020-02843-x |
| 20 | SUN P， ZHENG X， LI X. The Effects of CD73 on Gastrointestinal Cancer Progression and Treatment［J］. J Oncol， 2022，2022： 4330329. doi:10.1155/2022/4330329 |
| 21 | EBERHARDT N， BERGERO G， MAZZOCCO M Y， et al. Purinergic modulation of the immune response to infections［J］. Purinergic Signal， 2022，18（1）： 93-113. doi:10.1007/s11302-021-09838-y |
| 22 | ELSAGHIR A， EL-SABAA E， AHMED A K， et al. The Role of Cluster of Differentiation 39 （CD39） and Purinergic Signaling Pathway in Viral Infections［J］. Pathogens， 2023，12（2）：279. doi:10.3390/pathogens12020279 |
| 23 | CASEY M， SEGAWA K， LAW S C， et al. Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma［J］. Leukemia， 2023，37（2）： 379-387. doi:10.1038/s41375-022-01794-9 |
| 24 | IZAWA M， TANAKA N， MURAKAMI T， et al. Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer［J］. Lab Invest， 2023，103（4）： 100040. doi:10.1016/j.labinv.2022.100040 |
| 25 | BAJRACHARYA B， SHRESTHA D， TALVANI A， et al. The Ecto-5'nucleotidase/CD73 Mediates Leishmania amazonensis Survival in Macrophages［J］. Biomed Res Int， 2022，2022： 9928362. doi:10.1155/2022/9928362 |
| 26 | ANDERSEN J K， MILETIC H， HOSSAIN J A. Tumor-Associated Macrophages in Gliomas-Basic Insights and Treatment Opportunities［J］. Cancers （Basel）， 2022，14（5）：1319. doi:10.3390/cancers14051319 |
| 27 | WEI Q， ZHANG L， ZHAO N， et al. Immunosuppressive adenosine-targeted biomaterials for emerging cancer immunotherapy［J］. Front Immunol， 2022，13： 1012927. doi:10.3389/fimmu.2022.1012927 |
| 28 | NIE J， WANG D， LI M. The crosstalk between autophagy and myeloid-derived suppressor cell responses in cancer［J］. Clin Transl Oncol， 2023，25（10）： 2832-2840. doi:10.1007/s12094-023-03160-2 |
| 29 | KOWASH R R， AKBAY E A. Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer［J］. Front Immunol， 2023，14： 1130358. doi:10.3389/fimmu.2023.1130358 |
| 30 | LI L， WANG L， LI J， et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer［J］. Cancer Res， 2018，78（7）： 1779-1791. doi:10.1158/0008-5472.can-17-2460 |
| 31 | KIM H M， KANG M J， SONG S O. Metformin and Cervical Cancer Risk in Patients with Newly Diagnosed Type 2 Diabetes： A Population-Based Study in Korea［J］. Endocrinol Metab （Seoul）， 2022，37（6）： 929-937. doi:10.3803/enm.2022.1613 |
| 32 | WANG M， JIA J， CUI Y， et al. CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion［J］. Cell Death Dis， 2021，12（11）： 1065. doi:10.1038/s41419-021-04359-3 |
| 33 | AZAMBUJA J H， GELSLEICHTER N E， BECKENKAMP L R， et al. CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth［J］. Mol Neurobiol， 2019，56（5）： 3260-3279. doi:10.1007/s12035-018-1240-4 |
| 34 | GELSLEICHTER N E， AZAMBUJA J H， RUBENICH D S， et al. CD73 in glioblastoma： Where are we now and what are the future directions？［J］. Immunol Lett， 2023，256-257： 20-27. doi:10.1016/j.imlet.2023.03.005 |
| 35 | AZAMBUJA J H， SCHUH R S， MICHELS L R， et al. Blockade of CD73 delays glioblastoma growth by modulating the immune environment［J］. Cancer Immunol Immunother， 2020，69（9）： 1801-1812. doi:10.1007/s00262-020-02569-w |
| 36 | TSIAMPALI J， NEUMANN S， GIESEN B， et al. Enzymatic activity of CD73 modulates invasion of gliomas via epithelial-mesenchymal transition-like reprogramming［J］. Pharmaceuticals （Basel）， 2020，13（11）： 378. doi:10.3390/ph13110378 |
| 37 | ZHANG S， LI B， TANG L， et al. Disruption of CD73-Derived and Equilibrative Nucleoside Transporter 1-Mediated Adenosine Signaling Exacerbates Oxygen-Induced Retinopathy［J］. Am J Pathol， 2022，192（11）： 1633-1646. doi:10.1016/j.ajpath.2022.07.014 |
| 38 | YAN A， JOACHIMS M L， THOMPSON L F， et al. CD73 promotes glioblastoma pathogenesis and enhances its chemoresistance via A2B adenosine receptor signaling［J］. J Neurosci， 2019，39（22）： 4387-4402. doi:10.1523/jneurosci.1118-18.2019 |
| 39 | GOSWAMI S， WALLE T， CORNISH A E， et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma［J］. Nat Med， 2020，26（1）： 39-46. doi:10.1038/s41591-019-0694-x |
| 40 | AZAMBUJA J H， SCHUH R S， MICHELS L R， et al. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model［J］. Cancer Chemother Pharmacol， 2020，85（6）： 1177-1182. doi:10.1007/s00280-020-04077-1 |
| 41 | SAHA D， MARTUZA R L， RABKIN S D. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade［J］. Cancer Cell， 2017，32（2）： 253-267. doi:10.1016/j.ccell.2017.07.006 |
| 42 | LI L， TIAN Y. The role of metabolic reprogramming of tumor-associated macrophages in shaping the immunosuppressive tumor microenvironment［J］. Biomed Pharmacother， 2023，161： 114504. doi:10.1016/j.biopha.2023.114504 |
/
| 〈 |
|
〉 |